Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Harmony Biosciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.

Get HRMY alerts

About Andrew Serafin

The proxy statement of Harmony Biosciences Holdings, Inc. reports total compensation of $2,087,422 for Andrew Serafin in fiscal 2024, including a base salary of $420,294. Disclosed compensation is on record for 6 fiscal years. Harmony Biosciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Harmony Biosciences Holdings, Inc. includes Jeffrey Dayno (CEO), Jeffrey M. Dayno (CEO and Board Member), Peter Anastasiou (CEO, COO and Board Member) and 7 others.

Affiliation history

Company network

Leadership on record at Harmony Biosciences Holdings, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Harmony Biosciences Holdings, Inc. (HRMY) $420,294 $2,087,422
2023 Harmony Biosciences Holdings, Inc. (HRMY) $402,195 $647,425
2022 Harmony Biosciences Holdings, Inc. (HRMY) $375,673 $605,422
2021 Harmony Biosciences Holdings, Inc. (HRMY) — —
2020 Harmony Biosciences Holdings, Inc. (HRMY) — —
2019 Harmony Biosciences Holdings, Inc. (HRMY) — —

Recent activity

No call appearances or filed executive changes recorded yet.